BLOCK 13 WEEK 3 Flashcards
Heart Failure
Heart failure (HF), also known as congestive heart failure (CHF) and congestive cardiac failure (CCF), is defined as the failure of the heart to generate sufficient cardiac output to meet the metabolic demands of the body.
The prognosis for HF varies, but approximately 50% of those diagnosed are alive at 5 years.
Epidemiology of heart failure
HF is common: the prevalence in the UK is estimated at 1-2%.
HF primarily affects the elderly population: the average age of diagnosis is 75 years old. The incidence of HF has been increasing with the ageing population.
HF pathophysiology:
The pathophysiology for HF is diverse and depends on the aetiology of the HF.
How can HF be classified?
HF can be classified in different ways.
It can be classified as being:
- low output vs. high output HF
- predominantly systolic or diastolic dysfunction
- whether the process has been acute or chronic
- or by the severity of symptoms (and consideration for predominantly left or right ventricle features).
low output vs. high output HF
Low-output HF is much more common than high-output HF.
Low-output HF occurs: when cardiac output is reduced due to a primary problem with the heart and the heart is unable to meet the body’s needs.
High-output HF: refers to a heart that has a normal cardiac output, but there is an increase in peripheral metabolic demands that the heart is unable to meet.
Common causes of high output heart failure
The common causes of low-output HF wll be further discussed below. Common causes of high-output HF include:
Anaemia
Arteriovenous malformation
Paget’s disease
Pregnancy
Thyrotoxicosis
Thiamine deficiency (wet Beri-Beri)
Systolic vs Diastolic HF
Systolic dysfunction refers to an impairment of ventricular contraction.
The ventricles are able to fill well, but the heart is unable to pump the blood sufficiently out of the ventricle due to impaired myocardial contraction during systole (reduced ejection fraction).
Common causes include: ischaemic heart disease, dilated cardiomyopathy, myocarditis or infiltration (haemochromatosis or sarcoidosis).
Diastolic dysfunction refers to the inability of the ventricles to relax and fill normally, hence the heart is still able to pump well but pumps out less blood per contraction due to reduced diastolic filling (preserved ejection fraction).
Common causes include: uncontrolled chronic hypertension (significant left ventricular hypertrophy reduces filling of the left ventricle), hypetrophic cardiomyopathy, cardiac tamponade, and constrictive pericarditis.
Acute vs Chronic HF
HF can also be classified according to time of onset. Acute HF occurs with new-onset of HF symptoms (acute mitral regurgitation following an MI) or an acute deterioration in a patient with known, chronic HF.
In comparison, chronic HF progresses more slowly and may take many years to develop.
The clinical features of left heart failure
LHF, or left ventricular failure (LVF), causes pulmonary congestion (pressure builds up on the LHS of the heart and there is backpressure to the lungs) and there is systemic hypoperfusion.
Hypoperfusion: means low blood flow and occurs because of circulatory failure caused by the failing of the heart’s pumping action
Symptoms:
-Shortness of breath on exertion
-Orthopnoea: shortness of breath that occurs while lying flat and is relieved by sitting or standing
-Paroxysmal nocturnal dyspnoea
-Nocturnal cough (± pink frothy sputum)
-Fatigue
Signs:
Tachypnoea
Bibasal fine crackles on auscultation of the lungs
Cyanosis
Prolonged capillary refill time
Hypotension
Less common signs: pulsus alternans (alternating strong and weak pulse), S3 gallop rhythm (produced by large amounts of blood striking compliant left ventricle), features of functional mitral regurgitation.
The clinical features of right heart failure
Right heart failure causes venous congestion (pressure builds up behind the right heart) and pulmonary hypoperfusion (reduced right heart output).
Symptoms:
- Ankle swelling
- Weight gain
- Abdominal swelling and discomfort
- Anorexia and nausea
Signs:
-Raised JVP
-Pitting peripheral oedema (ankle to thighs to sacrum)
-Tender smooth hepatomegaly
-Ascites
-Transudative pleural effusions (typically bilaterally)
Congestive Cardiac Heart Failure
Sometimes left sided heart failure can lead to pulmonary congestion which in turn also pushes the right ventricle into failure. In these cases signs and symptoms of both left and right sided heart failure may be present. This is congestive cardiac failu
Ejection Fraction
Chronic heart failure symptoms
Signs on examination include:
- Tachycardia (raised heart rate)
- Tachypnoea (raised respiratory rate)
- Hypertension
- Murmurs on auscultation indicating valvular heart disease
- 3rd heart sound on auscultation
- Bilateral basal crackles (sounding “wet”) on auscultation of the lungs, indicating pulmonary oedema
- Raised jugular venous pressure (JVP), caused by a backlog on the right side of the heart, leading to an engorged internal jugular vein in the neck
- Peripheral oedema of the ankles, legs and sacrum
Location
Investigating Heart Failure
- Clinical assessment (history and examination)
- N-terminal pro-B-type natriuretic peptide (NT‑proBNP) blood test
- ECG:
ECG may be normal or hint at underlying aetiology (ischaemic changes or arrhythmias). - Echocardiogram
-Transthoracic echocardiogram (TTE)
Echocardiogram will confirm the presence and degree of ventricular dysfunction.
Other investigations include:
-Bloods for anaemia, renal function, thyroid function, liver function, lipids and diabetes
-Chest x-ray and lung function tests to exclude lung pathology
New York Heart Association Classification
The New York Heart Association (NYHA) classification system is used to grade the severity of symptoms related to heart failure. Here is a simplified summary:
Class I: No limitation on activity
Class II: Comfortable at rest but symptomatic with ordinary activities
Class III: Comfortable at rest but symptomatic with any activity
Class IV: Symptomatic at rest
MANAGEMENT OF HEART FAILURE
There are five principles of management. You can remember this with the “RAMPS” mnemonic:
R – Refer to cardiology
A – Advise them about the condition
M – Medical treatment
P – Procedural or surgical interventions
S – Specialist heart failure MDT input, such as the heart failure specialist nurses, for advice and support
The urgency of the referral and specialist assessment depends on the NT-proBNP result. According to the NICE guidelines:
From 400 – 2000 ng/litre should be seen and have an echocardiogram within 6 weeks
Above 2000 ng/litre should be seen and have an echocardiogram within 2 weeks
Medical Treatment of Heart Failure
The first-line medical treatment of chronic heart failure can be remembered with the “ABAL” mnemonic:
A – ACE inhibitor (e.g., ramipril) titrated as high as tolerated
B – Beta blocker (e.g., bisoprolol) titrated as high as tolerated
A – Aldosterone antagonist when symptoms are not controlled with A and B (e.g., spironolactone or eplerenone)
L – Loop diuretics (e.g., furosemide or bumetanide)
An angiotensin receptor blocker (ARB) (e.g., candesartan) can be used instead of an ACE inhibitor if not tolerated. Avoid ACE inhibitors in patients with valvular heart disease until initiated by a specialist.
Aldosterone antagonists are used when there is a reduced ejection fraction and symptoms are not controlled with an ACEi and beta blocker.
Patients should have their U&Es closely monitored whilst taking diuretics, ACE inhibitors and aldosterone antagonists, as all three medications can cause electrolyte disturbances. It is particularly essential to closely monitor the renal function in patients taking ACE inhibitors and aldosterone antagonists. Both can cause hyperkalaemia (raised potassium), which is potentially fatal.
Additional specialist
Loop diuretics
ACE inhibitors and ARBS
DIGOXIN
Side effects of Beta Blockers
SGLT- 2 Inhibitors
Treatment
Surgical Procedures
Surgical procedures may be used to treat underlying valvular heart disease.
Implantable cardioverter defibrillators continually monitor the heart and apply a defibrillator shock to cardiovert the patient back into sinus rhythm if they identify a shockable arrhythmia. These are used in patients who previously had ventricular tachycardia or ventricular fibrillation
Differential Diagnosis
Valvular Disease
The three types of heart valve diseases are regurgitation, stenosis, and atresia.
The type of heart valve disease you have depends on which valve is affected and in what way.
Heart valve diseases can cause problems in any of the heart’s four valves: the aortic, mitral, pulmonary, and tricuspid valves
CORONARY ARTERIES
- The left anterior descending artery is sometimes called the ANTERIOR INTERVENTICULAR ARTERY
-
Left Marginal Artery
- The left marginal artery goes down (vertical)
- The left circumflex artery goes across (horizontal)
Stroke Volume
Stroke Volume: The volume of blood pumped from the left ventricle per beat
Cardiac Output
Cardiac Output: The volume of blood pumped out of the heart per minute
Ejection Fraction
Is a measurement expressed as a percentage of how much blood the left ventricle pumps out with each contraction
Arteries of Heart
CORONARY VEINS
-drain deoxygenated blood from coronary distribution and return it to the right atrium so it can be reoxygenated.
-A number of cardiac veins run alongside the cardiac arteries
e.g the great cardiac veins runs along the left anterior descending
-All of the cardiac veins drain into the coronary sinus which then takes the blood to the coronary sinus in the right atrium.
-Some veins carry deoxygenated blood back to the right atrium without going through the coronary sinus such as the smallest cardiac vein (thebesian vein) and the anterior cardiac vein
Ligamentum Arteriosum
This small ligamentous attachment runs between the aortic arch and left pulmonary artery.
Conus arteriosus
Space between the right ventricle and the pulmonary trunk
Electrocardiogram
ECG is an electrocardiogram.
its a simple test that can be used to check your hearts rhythm and electrical activity.
Describe atrial fibrillation on an ECG ?
The R waves are irregular
There’s no p waves
There’s no F waves
Atrial Fibrillation
The R waves are irregular
There’s no p waves
There’s no F waves
Why is Digoxin no longer used to treat atrial fibrillation ?
Digoxin is no longer used to treat atrial fibrillation because it can cause arrythmia
Atrial Fibrillation Pathophysiology
Normally, the sinoatrial node produces organised electrical activity that coordinates the contraction of the atria.
Atrial fibrillation occurs when this electrical activity is disorganised, causing the contraction of the atria to become uncoordinated, rapid and irregular.
This chaotic electrical activity overrides the regular, organised activity from the sinoatrial node. It passes through to the ventricles, resulting in irregularly irregular ventricular contraction.
Uncoordinated atrial activity means the blood can stagnate in the atria, forming a blood clot (thrombus).
A thrombus formed in the left atrium may travel to the brain and block a cerebral artery, causing an ischaemic stroke.
The risk of stroke is about 5 times higher than usual in patients with atrial fibrillation (depending on individual factors).
What are the overall effects of atrial fibrillation ?
The overall effects of atrial fibrillation are:
-Irregularly irregular ventricular contractions
-Tachycardia (fast heart rate)
-Heart failure due to impaired filling of the ventricles during diastole
-Increased risk of stroke
What are the most common causes of atrial fibrillation?
The most common causes of atrial fibrillation can be remembered with the “SMITH” mnemonic:
S – Sepsis
M – Mitral valve pathology (stenosis or regurgitation)
I – Ischaemic heart disease
T – Thyrotoxicosis aka hyperthyroidism
H – Hypertension
Alcohol and caffeine are lifestyle causes worth remembering.
How does AF Present?
Presentation
Patients are often asymptomatic, and atrial fibrillation is an incidental finding. It may be diagnosed after a stroke.
Patients may present with:
-Palpitations
-Shortness of breath
-Dizziness or syncope (loss of consciousness)
-Symptoms of associated conditions (e.g., stroke, sepsis or thyrotoxicosis)
The key examination finding is an irregularly irregular pulse. There are two differential diagnoses for an irregularly irregular pulse:
Atrial fibrillation
Ventricular ectopics
Ventricular ectopics disappear when the heart rate gets above a certain threshold. Therefore, a regular heart rate during exercise suggests a diagnosis of ventricular ectopics.
Investigations of AF
Investigations
An ECG is required in all patients with an irregularly irregular pulse. The ECG findings in atrial fibrillation are:
Absent P waves
Narrow QRS complex tachycardia
Irregularly irregular ventricular rhythm
An echocardiogram may be required to investigate further in cases of:
Valvular heart disease
Heart failure
Planned cardioversion
Paroxysmal Atrial Fibrillation
Paroxysmal atrial fibrillation refers to episodes of atrial fibrillation that reoccur and spontaneously resolve back to sinus rhythm. These episodes can last between 30 seconds and 48 hours.
Patients with a normal ECG and suspected paroxysmal atrial fibrillation can have further investigations with:
24-hour ambulatory ECG (Holter monitor)
Cardiac event recorder lasting 1-2 weeks
Valvular atrial fibrillation
Valvular atrial fibrillation is AF with significant mitral stenosis or a mechanical heart valve. The assumption is that the valvular pathology has led to atrial fibrillation. Atrial fibrillation without valve pathology or with other valve pathologies, such as mitral regurgitation or aortic stenosis, is classed as non-valvular AF.
The NICE guidelines (2021) do not reference valvular atrial fibrillation. They recommend patients with valvular heart disease are referred to a cardiologist for further assessment and management.
Principles of management
Management here is based on the NICE guidelines from 2021. Follow local and national guidelines when treating patients.
There are two principles to treating atrial fibrillation:
-Rate or rhythm control
-Anticoagulation to prevent strokes
RATE CONTROL
The function of the atria is to pump blood into the ventricles. In patients with atrial fibrillation, the atrial contractions are not coordinated, so the ventricles must fill by suction and gravity, which is considerably less efficient. The higher the heart rate, the less time is available for the ventricles to fill with blood, reducing the cardiac output. Rate control aims to get the heart rate below 100 and extend the time during diastole for the ventricles to fill with blood.
NICE guidelines (2021) suggest all patients with AF should have rate control as first-line, except with:
A reversible cause for their AF
New onset atrial fibrillation (within the last 48 hours)
Heart failure caused by atrial fibrillation
Symptoms despite being effectively rate controlled
Options for rate control:
Beta blocker first-line (e.g., atenolol or bisoprolol)
Calcium-channel blocker (e.g., diltiazem or verapamil) (not preferable in heart failure)
Digoxin (only in sedentary people with persistent atrial fibrillation, requires monitoring and has a risk of toxicity)
RHYTHM CONTROL
Rhythm control may be offered to patients with:
-A reversible cause for their AF
-New onset atrial fibrillation (within the last 48 hours)
-Heart failure caused by atrial fibrillation
-Symptoms despite being effectively rate controlled
Rhythm control aims to return the patient to normal sinus rhythm. This can be achieved through:
-Cardioversion
-Long-term rhythm control using medications
CARDIOVERSION
Cardioversion is a medical procedure that uses quick, low-energy shocks to restore a regular heart rhythm. It’s a treatment for certain types of irregular heartbeats (arrhythmias), including atrial fibrillation (A-fib)
For cardioversion, there is a choice between:
- Immediate cardioversion
- Delayed cardioversion
Immediate Cardioversion
Immediate cardioversion is used if the atrial fibrillation is either:
-Present for less than 48 hours
-Causing life-threatening haemodynamic instability
There are two options for immediate cardioversion:
-Pharmacological cardioversion
-Electrical cardioversion
Pharmalogical Cardioversion
- Flecainide
- Amiodarone (the drug of choice in patients with structural heart disease)
Electrical Cardioversion
Electrical cardioversion aims to shock the heart back into sinus rhythm. It involves using a cardiac defibrillator machine to deliver controlled shocks. This is usually done with sedation or general anaesthesia.
Delayed Cardioversion
Delayed cardioversion is used if the atrial fibrillation has been present for more than 48 hours and they are stable. Electrical cardioversion is recommended.
Transoesophageal echocardiography‑guided cardioversion is an option where available. Amiodarone may be considered before and after electrical cardioversion to prevent AF from recurring.
The patient should be anticoagulated for at least 3 weeks before delayed cardioversion. During the 48 hours before cardioversion, they may have developed a blood clot in the atria, and reverting them to sinus rhythm carries a high risk of mobilising that clot, causing a stroke. They are rate controlled whilst waiting for cardioversion.
Long term rhythm control
- Beta blockers first-line
- Dronedarone second-line for maintaining normal rhythm where patients have had successful cardioversion
- Amiodarone is useful in patients with heart failure or left ventricular dysfunction
Management of Paroxysmal Atrial Fibrillation
Patients with paroxysmal atrial fibrillation may be appropriate for a “pill-in-the-pocket” approach. They take a pill to terminate their atrial fibrillation only when they feel the symptoms starting. To be suitable for a pill-in-the-pocket approach, they must have infrequent episodes without structural heart disease. They also need to be able to identify the signs of atrial fibrillation and understand when to take the treatment.
Flecainide is the usual treatment for a pill-in-the-pocket approach. There is a risk of flecainide converting the atrial fibrillation into atrial flutter, with 1:1 AV conduction to the ventricles, causing a very fast ventricular rate.
Patients with paroxysmal atrial fibrillation should still be anticoagulated based on their CHA2DS2-VASc score, similar to permanent atrial fibrillation.
ABLATION
Ablation is a procedure to treat atrial fibrillation. It uses small burns or freezes to cause some scarring on the inside of the heart to help break up the electrical signals that cause irregular heartbeats. This can help the heart maintain a normal heart rhythm.
ABLATION
Where drug treatment for rate or rhythm control is not adequate or tolerated, there are two options for ablation:
- Left atrial ablation
- Atrioventricular node ablation and a permanent pacemaker
Left atrial ablation is performed in a catheter laboratory, often called a “cath lab”. It involves a general anaesthetic or sedation. A catheter is inserted into a femoral vein and fed through the venous system under x-ray guidance to the heart. The catheter punctures through the septum into the left atrium. Once in the left atrium, it is placed against different areas to test the electrical signals. The operator attempts to identify the location of any abnormal electrical pathways. Once identified, radiofrequency ablation (heat) is applied to burn the abnormal area of electrical activity. This leaves scar tissue that does not conduct electrical activity. The aim is to remove the source of the arrhythmia and restore normal sinus rhythm.
Atrioventricular node ablation involves destroying the connection between the atria and ventricles (the atrioventricular node). It is a catheter procedure. After the procedure, the irregular electrical activity in the atria cannot pass through to the ventricles. A permanent pacemaker is required to control ventricular contraction (the pacemaker is inserted before the ablation procedure). Anticoagulation is still needed to prevent strokes.
ANTICOAGULATION
Anticoagulation
Uncontrolled and unorganised activity in the atria leads to blood stagnating in the left atrium, particularly in the left atrial appendage. Eventually, this stagnated blood leads to a thrombus (clot). This thrombus then mobilises (becomes an embolus) and travels from the left atrium to the left ventricle, into the aorta and up in the carotid arteries to the brain. It can then lodge in a cerebral artery and cause an ischaemic stroke.
Anticoagulation treatment reduces coagulation (thrombus formation) by interfering with the clotting cascade. Without anticoagulation, patients with atrial fibrillation have around a 5% risk of stroke each year, depending on individual factors. With anticoagulation, patients with atrial fibrillation have around a 1-2% risk of stroke each year, depending on individual factors. Anticoagulation reduces the risk of stroke by about 2/3.
Anticoagulation treatment carries around a 2.5-8% risk of serious bleeding each year, depending on individual factors.
The NICE guidelines (2021) recommend for anticoagulation:
- Direct-acting oral anticoagulants (DOACs) first-line
- Warfarin second-line, if DOACs are contraindicated
DOACs
Direct-Acting Oral Anticoagulants
Direct-acting oral anticoagulants (DOACs) are oral anticoagulants that do not require INR monitoring, unlike warfarin. They are suitable for most patients, including patients with cancer. They have a 6-14 hour half-life.
Apixaban, edoxaban and rivaroxaban are direct factor Xa inhibitors. Dabigatran is a direct thrombin inhibitor.
Apixaban and dabigatran are taken twice daily, and edoxaban and rivaroxaban are taken once daily.
Some of the DOACs have agents available to reverse the effects in uncontrolled or life-threatening bleeding:
Andexanet alfa (apixaban and rivaroxaban)
Idarucizumab (a monoclonal antibody against dabigatran)
DOACs have several advantages compared with warfarin:
No monitoring is required
No issues with time in therapeutic range (provided they have good adherence)
No major interaction problems
Equal or slightly better than warfarin at preventing strokes in atrial fibrillation
Equal or slightly lower risk of bleeding than warfarin
The most common indications for DOACs are:
Stroke prevention in patients with atrial fibrillation
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
Prophylaxis of venous thromboembolism (DVTs and PEs) after a hip or knee replacement